Since Anika Therapeutics Inc. (NASDAQ:ANIK) and Heat Biologics Inc. (NASDAQ:HTBX) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation of both companies.

Valuation and Earnings

In table 1 we can see Anika Therapeutics Inc. and Heat Biologics Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 represents Anika Therapeutics Inc. (NASDAQ:ANIK) and Heat Biologics Inc. (NASDAQ:HTBX)’s return on assets, return on equity and net margins.

Volatility and Risk

Anika Therapeutics Inc.’s 1.11 beta indicates that its volatility is 11.00% more volatile than that of S&P 500. Heat Biologics Inc.’s 1.83 beta is the reason why it is 83.00% more volatile than S&P 500.

Liquidity

Anika Therapeutics Inc.’s Current Ratio and Quick Ratio are 18.1 and 16.1 respectively. The Current Ratio and Quick Ratio of its competitor Heat Biologics Inc. are 5.7 and 5.7 respectively. Anika Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Heat Biologics Inc.

Analyst Recommendations

Ratings and Recommendations for Anika Therapeutics Inc. and Heat Biologics Inc. can be find in next table.

On the other hand, Heat Biologics Inc.’s potential upside is 1,303.51% and its average price target is $8.

Institutional and Insider Ownership

Roughly 96.6% of Anika Therapeutics Inc. shares are owned by institutional investors while 10.9% of Heat Biologics Inc. are owned by institutional investors. 0.9% are Anika Therapeutics Inc.’s share owned by insiders. Competitively, 3.62% are Heat Biologics Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Anika Therapeutics Inc. has 63.91% stronger performance while Heat Biologics Inc. has -27.53% weaker performance.

Summary

On 8 of the 9 factors Anika Therapeutics Inc. beats Heat Biologics Inc.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The companyÂ’s dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.